In Alzheimer’s disease, plasma glial fibrillary acidic protein levels may be a better biomarker of amyloid-β pathology than cerebrospinal fluid levels, especially in preclinical disease.
Why this matters
Glial fibrillary acidic protein is a marker of reactive astrogliosis that is elevated in the cerebrospinal fluid and blood of people with Alzheimer’s disease.
This study was the first to examine whether elevations in plasma glial fibrillary acidic protein levels occur across the entire Alzheimer’s disease continuum; the findings could help to facilitate the detection of Alzheimer’s disease, particularly at the preclinical stage. Earlier detection would permit timely interventions and ultimately better outcomes in Alzheimer’s disease.